Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches.
The PI3K-AKT-mTOR pathway is often a commonly disrupted pathway in human cancer and, therefore, it is widely exploited for cancer therapy. The inhibitors for the important proteins of the pathway including PI3K and mTOR have been increasingly designed. The dual inhibitors targeting PI3K and mTOR bot...
Main Author: | Mohd Rehan |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0219180 |
Similar Items
-
Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
by: Zhao H, et al.
Published: (2019-07-01) -
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
by: Chiara Tarantelli, et al.
Published: (2020-02-01) -
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
by: Keiko Shoji, et al.
Published: (2012-01-01) -
PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01) -
Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors
by: Bingbing Zhao, et al.
Published: (2018-06-01)